Icon Legend

This session is not on your agenda.

This session is on your agenda. Click again to remove it.

Presentation Icons

ACVIM Resident Research Award Eligible

Additional Fees May Be Required

By Invite Only

Capturing for On Demand

Cardiology Research Abstract Award Eligible

ERC Approved Lecture for ACVIM Residency

Poster

Livestream

One Health

Pre-Registration Required

Research Abstract

Specialty Symposium

ACVIM Resident Research Award Winner

Cardiology Research Abstract Award Winner

3 Views

Oncology

Mast Cell Tumor: Year in Review

Thursday, June 11, 2026

1:45 PM - 2:45 PM PT

Pending CE: 1.0 Medical Hours

Primary Presenter(s)

Philip J. Bergman, DVM, PhD, DACVIM (Oncology)

Director, Veterinary Program
Focused Ultrasound Foundation
Stamford, Connecticut, United States

Co-Presenter(s)

Douglas H. Thamm, VMD, DACVIM (Oncology) (he/him/his)

Professor and Stuart Presidential Chair in Oncology
Colorado State University
Fort Collins, Colorado, United States

Disclosure(s):

Philip J. Bergman, DVM, PhD, DACVIM (Oncology): Focused Ultrasound Foundation: Advisor (Ongoing)

Presentation Description / Summary: This lecture will be a follow-on lecture from the 2025 Forum "Lymphoma Year in Review" by Drs. Thamm & Bergman, but will be a year in review instead on Mast Cell Tumors. We will take all of the 2025 publications on mast cell tumors and triage them for importance and then collate them into categories such as Diagnostics, In vitro improvements, Clinical Advances, etc. depending on the types of publications. We will then present a rapid-fire summary of each publication with supporting figures and tables and then spend a small amount of time after each publication and provide feedback on possible next best steps for future research in that area.

Learning Objectives:

Upon completion, participants will be more fluent on the recent publications concerning canine mast cell tumor diagnosis, treatment and prognosis.
Upon completion, participants will better understand the in vitro advances made in 2025 for veterinary patients with mast cell tumors.